RxDoctor Payments Data

Patrick Dermody, MD

Family Medicine · Napa, CANPI 1629483565

Payments from drug & device makers

$951in general payments, 2019–2025

Across 56 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$405
  • Novartis$183
  • Medtronic$144
  • Amarin Pharma, Inc.$69
  • OPKO Pharmaceuticals, LLC$39
  • Hologic Sales And Service, LLC$36
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$91296%
  • Education$394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$951 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$402,876
Medicare patients
752
Services billed
4,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$85,836
OzempicSemaglutide53$63,931
JardianceEmpagliflozin21$26,193
JanuviaSitagliptin Phosphate22$23,008
XareltoRivaroxaban20$17,853
Memantine Hcl ErMemantine Hcl13$4,588
Atorvastatin Calcium448$4,205
Levothyroxine Sodium210$2,845
Omeprazole122$2,667
Metoprolol Succinate162$2,430
Tamsulosin Hcl126$2,372
SynthroidLevothyroxine Sodium34$2,368
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,131
Albuterol Sulfate HfaAlbuterol Sulfate66$1,916
Lisinopril162$1,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$63,93153 claims
Johnson & JohnsonXarelto$26$17,85320 claims
AbbVieSynthroid$405$2,36834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Napa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →